Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019

October 16, 2019 — Researchers have shown for the first time in preclinical studies that the...

Philips Introduces New 200mm and 150mm Stellarex 0.035-inch Low-dose Drug-coated Balloons
News | Drug-Eluting Balloons | October 15, 2019

October 15, 2019 — Royal Philips introduced two new balloons to its Stellarex 0.035-inch low-dose...

Pesticide Exposure May Increase Heart Disease and Stroke Risk

Image courtesy of zefe wu from Pixabay

News | Cardiac Diagnostics | October 15, 2019

October 15, 2019 — On-the-job exposure to high levels of pesticides raised the...

Kardium Announces Successful Results From GLOBAL-AF Study
News | EP Mapping and Imaging Systems | October 15, 2019

October 15, 2019 — Kardium Inc. announced that the Globe...

FDA Issues Final Guidances on Guidewires, Intravascular Catheters and Delivery Systems
News | Guidewires | October 11, 2019

October 11, 2019 — The U.S. Food and Drug Administration (FDA) issued two final guidances for the performance...

Medtronic Initiates Worldwide Pivotal Study of Extravascular Implantable Cardioverter Defibrillator
News | Implantable Cardioverter Defibrillator (ICD) | October 11, 2019

October 11, 2019 — Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational...

An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no statistically significant mortality increase. This was one of the first major reviews of trial data for patients who were treated with a paclitaxel coated device used in peripheral vessels following a meta analysis study of paclitaxel device trials published in December 2018 that showed a mortality safety signal. This was a major discussion during the FDA townhall meeting at the #TCT2019.
News | Drug-Eluting Balloons | October 10, 2019

October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no...

BackBeat CNT is the flagship therapy of Orchestra BioMed Inc. It is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).

The BackBeat CNT system is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS). 

News | Hypertension | October 10, 2019

October 10. 2019 — Late-breaking results from its MODERATO II double-blind, randomized study of BackBeat Cardiac...

TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-...

Fujifilm Upgrades Next-Generation Synapse Cardiology PACS
News | Cardiac PACS | October 10, 2019

October 9, 2019 – Fujifilm Medical Systems U.S.A. Inc. recently launched Synapse...

Overlay Init